Before use: Have an electrocardiogram (routine) or/and cardiac ultrasound (routine). Exclude arrhythmias, severe conduction block, congenital heart disease and other disorders; exclude bronchitis, pneumonia, asthma. CONTRAINDICATIONS: Propranolol, a traditional medication that has been used for decades, is contraindicated by its insertion in cardiac pathology (conduction block), airway sensitization disorders, dyspnea, or other pulmonary disorders. Dosage: 1 mg/kg/day in 2-3 oral doses during the first week; thereafter, 2 mg/kg/day in 2-3 oral doses according to the child’s weight. Method of administration: Feed the medicine 10-15 minutes after breastfeeding, crush the tablets, put them in a spoon, dissolve them in 10mL of sugar water or milk (milk powder), and pour them into the mouth at once. It should be given 3 times a day at intervals of 6-8 h. If the infant does not cooperate and spits out the medicine, try to make up the dose. Propranolol should be taken during the daytime after food intake, and infants <6 weeks of age should be fed at least once every 4 hours, infants 6 weeks to 4 months of age should be fed at least once every 5 hours, and infants 4 months of age should be fed at least once every 6 to 8 hours. Hypoglycemia can be avoided by taking the drug after eating. The plasma half-life is 3-6 h after oral administration of Xanax. Parents: Diarrhea, hypotension, bradycardia, hypoglycemia, tracheal spasm and other complications may occur after administration of the drug. If diarrhea is severe, the drug needs to be stopped and taken again after the symptoms have completely disappeared and adapted. If induced tracheal or bronchial spasm, asthma, need to stop immediately, and can not continue to use the drug. Hypotension and bradycardia generally have no subjective symptoms and do not require treatment. Regular monitoring of blood glucose is required, and blood glucose should be rechecked 1 week after administration and every 1-2 months thereafter, and the drug should be stopped immediately in case of hypoglycemia. During treatment, vaccination can be received normally. If high fever and cough occur due to cold, the medicine should be temporarily stopped and continued after the cold is cured. Other special circumstances, need to be repeated at any time. Post-treatment response: The effective rate of propranolol can be as high as 90% or more. After 1 week of oral propranolol, the color of the tumor begins to fade, shrink and soften. After 3 months of treatment, most of the tumors shrink significantly. By the age of 1 year, the tumors have almost disappeared, and capillary dilatation may remain on the surface. Significant changes are seen in the first 8 weeks of treatment and at 6 months of age. Course: The effect of propranolol on hemangiomas is most pronounced during the first week, after which the improvement is slow and sometimes there is a period of stagnation. The reason for this may be the early presumed vasoconstrictor effect, while the drug's effect on molecular markers of hemangiomas is not clinically evident. However, drug therapy must be continued for at least 6 months, as premature discontinuation can lead to rebound. Discontinuation criteria: complete regression of the hemangioma, or age over 1 year and end of the proliferative phase of the hemangioma. Strictly following the doctor's instructions to take the medication and not reducing or stopping the medication without authorization, except in the case of serious complications or other systemic diseases, is crucial to avoid recurrence or rebound. Discontinuation method: halve the number of times in the first 2 weeks, halve the dosage in the second 2 weeks, and stop the drug. Observe for 1 month, if there is no rebound, complete the discontinuation; if rebound, continue to take the drug for 1 month or longer according to the original regimen. Safety: Studies have confirmed that propranolol does not affect the growth and development of children with IH, nor does it affect the secretion of growth hormone. Psychologically, studies have confirmed that oral propranolol does not affect the psychological development of children with IH. The safety of propranolol is widely recognized by scholars from various countries. Currently, the American Academy of Pediatricians and the American Academy of Dermatologists recommend propranolol as one of the drugs of choice for the treatment of progressive refractory infantile hemangiomas (intermediate- and high-risk infantile hemangiomas).